Sign in

MDWD on Nasdaq

MediWound Ltd.

MediWound Ltd. is a medicinal chemicals and botanical products company based in Yavne.1 Its shares trade on Nasdaq under the symbol MDWD.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$17.0MRevenue, fiscal 20252
-$23.9MNet income, fiscal 20252

Compare with FITLIFE BRANDS, INC., Bon Natural Life Ltd or Charlie's Holdings, Inc., or pick any stock.

  • TickerMDWD on Nasdaq1
  • IndustryMedicinal Chemicals & Botanical Products1
  • HeadquartersL31
  • Incorporated inIsrael3
  • Business address42 Hayarkon Street, Yavne, L3 81227453
  • Filer categoryAccelerated filer3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

19.2%Gross margin2
-149.0%Operating margin2
-140.8%Net margin2
-16.1%Revenue growth, 20252
-54.7%Return on equity2
-$21.6MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue35¢$13.7M
  • Research and development37¢$14.3M
  • Selling, general and admin22¢$8.4M
  • Interest6¢$2.5M
  • Income tax0¢$169.0K

Out of $17.0M in revenue.2 The company lost money this year.

Financial statements

Revenue456782$17.0M in 2025+399% since 2018
0$10.0M$20.0M$30.0M$40.0M2018: $3.4M$3.4M20182019: $31.8M$31.8M2019+835%2020: $21.8M$21.8M2020−32%2021: $23.8M$23.8M2021+9%2022: $26.5M$26.5M2022+12%2023: $18.7M$18.7M2023−29%2024: $20.2M$20.2M2024+8%2025: $17.0M$17.0M2025−16%
Gross profit456782$3.3M in 2025+148% since 2018
0$5.0M$10.0M$15.0M$20.0M2018: $1.3M$1.3M20182019: $19.9M$19.9M2019+1419%2020: $7.5M$7.5M2020−62%2021: $8.8M$8.8M2021+16%2022: $13.2M$13.2M2022+50%2023: $3.6M$3.6M2023−73%2024: $2.6M$2.6M2024−26%2025: $3.3M$3.3M2025+24%
Operating income456782-$25.3M in 2025+538% since 2018
-$30.0M-$20.0M-$10.0M0$10.0M2018: -$4.0M-$4.0M20182019: $4.5M$4.5M20192020: -$8.8M-$8.8M20202021: -$11.2M-$11.2M2021+27%2022: -$8.3M-$8.3M2022−26%2023: -$15.3M-$15.3M2023+83%2024: -$19.4M-$19.4M2024+27%2025: -$25.3M-$25.3M2025+30%
Net income456782-$23.9M in 2025+2159% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M0$10.0M2018: -$1.1M-$1.1M20182019: $5.0M$5.0M20192020: -$9.2M-$9.2M20202021: -$13.6M-$13.6M2021+47%2022: -$19.6M-$19.6M2022+45%2023: -$6.7M-$6.7M2023−66%2024: -$30.2M-$30.2M2024+350%2025: -$23.9M-$23.9M2025−21%
Fiscal year20182019202020212022202320242025
Revenue$3.4M4$31.8M5$21.8M6$23.8M7$26.5M8$18.7M2$20.2M2$17.0M2
Cost of revenue$15.0M7$13.3M8$15.1M2$17.6M2$13.7M2
Gross profit$1.3M4$19.9M5$7.5M6$8.8M7$13.2M8$3.6M2$2.6M2$3.3M2
Research and development$10.3M7$10.2M8$7.5M2$8.9M2$14.3M2
Selling, general and admin$6.3M7$6.9M8$6.8M2$8.2M2$8.4M2
Operating income-$4.0M4$4.5M5-$8.8M6-$11.2M7-$8.3M8-$15.3M2-$19.4M2-$25.3M2
Interest$2.3M7$11.6M8$1.9M2$12.8M2$2.5M2
Income before tax-$13.5M7-$19.5M8-$6.5M2-$30.2M2-$23.7M2
Income tax$27.0K7$78.0K8$185.0K2$61.0K2$169.0K2
Net income-$1.1M4$5.0M5-$9.2M6-$13.6M7-$19.6M8-$6.7M2-$30.2M2-$23.9M2
Earnings per share-$2.386-$3.487-$3.938-$0.752-$3.032-$2.102
Earnings per share (diluted)-$2.386-$3.487-$3.938-$0.752-$3.032-$2.102
Shares (weighted, basic)3.9M shares75.0M shares89.0M shares210.0M shares211.4M shares2
Shares (weighted, diluted)3.9M shares75.0M shares89.0M shares210.0M shares211.4M shares2

Compare MediWound Ltd. with another company

Corporate structure

MediWound Ltd. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of MediWound Ltd.

  • MediWound Ltd. L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MediWound Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$18.6M2 Dec 31, 2025$14.1M2 Dec 31, 2024+31.9%
Operating-lease assets (leased space)$7.2M2 Dec 31, 2025$6.7M2 Dec 31, 2024+7.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.8M2 Dec 31, 2025$9.2M2 Dec 31, 2024−47.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$33.0K2 Dec 31, 2025$99.0K2 Dec 31, 2024−66.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$4.1M2 Dec 31, 2025$2.7M2 Dec 31, 2024+52.0%

Leadership

Who has led MediWound Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ofer Gonen2026–now

Chief financial officer

  1. Kalfon Hana Luxenburg2026–now

Chief operating officer

  1. Shmuel Hess2026–now
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerBoaz Gur-Lavie named Oct 4, 2022 to Oct 6, 202222
  • Executive OfficerLior R. Rosenberg named Oct 4, 2022 to Oct 6, 202222
  • Executive OfficerTzvi R. Palash named Oct 4, 2022 to Oct 6, 202222
  • DirectorAssaf R. Segal named Oct 4, 2022 to Oct 6, 202222
  • DirectorNissim R. Mashiach named Oct 4, 2022 to Oct 6, 202222
  • DirectorSharon R. Kochan named Oct 4, 2022 to Oct 6, 202222
  • DirectorSharon R. Malka named Oct 4, 2022 to Oct 6, 202222

Timeline

  1. Mar 18, 2026New chief executive Ofer Gonen becomes CEO11

Calendar

Coming up

  1. Nov 19, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.24) a share, on Nov 20, 2025.23

Drug trials and FDA: coming up

  1. Dec 2026Phase 3 trial readout expected Phase 3 trial of EscharEx (EX-03) in Venous Leg Ulcer (VLU): primary completion expected Dec 2026 (ClinicalTrials.gov NCT06568627).24

Drug trials and FDA: recently

  1. Aug 15, 2024FDA approved a new use FDA approved an efficacy supplement for Nexobrid (anacaulase-bcdb), a new use or patient group (BLA 761192, supplement 10).25

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

191 filings to the SEC since October 2021: 5 annual reports, 16 insider forms, 36 large holders, 2 private raises, 132 other. The latest 20:

  1. Sep 2, 20264 EDGAR
  2. Aug 28, 2026SCHEDULE 13G/A EDGAR
  3. Aug 28, 2026144 EDGAR
  4. Aug 28, 20264 EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 13, 20266-K EDGAR
  7. Jun 4, 20264 EDGAR
  8. Jun 2, 20264 EDGAR
  9. Jun 1, 20264 EDGAR
  10. May 27, 20266-K EDGAR
  11. May 15, 2026SCHEDULE 13G EDGAR
  12. May 6, 20266-K EDGAR
  13. Apr 2, 20266-K EDGAR
  14. Mar 30, 20266-K EDGAR
  15. Mar 25, 20263 EDGAR
  16. Mar 18, 20263 EDGAR
  17. Mar 18, 20263 EDGAR
  18. Mar 18, 20263 EDGAR
  19. Mar 18, 20263 EDGAR
  20. Mar 18, 20263 EDGAR

The 191 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 4 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 1, 2026Rubinstein SamuelDirectorBuy525$12.62$6.6KForm 4
Sep 1, 2026Rubinstein SamuelDirectorSale525$12.72$6.7KForm 4
Aug 27, 2026Hess ShmuelCOO & Chief Commercial OfficerSale3,958$12.93$51.2KForm 4
Aug 26, 2026Hess ShmuelCOO & Chief Commercial OfficerSale1,865$13.00$24.2KForm 4
Jun 3, 2026SHAMIR NACHUMDirectorBuy6,000$14.00$84.0KForm 4
Jun 1, 2026Fox David MortonDirectorBuy3,537$14.11$49.9KForm 4
May 29, 2026Rubinstein SamuelDirectorBuy150$14.33$2.1KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$30.5M 2022–2022
Money received by yearMoney received by year, 2022–2022: $30.5M in all. Private raises (Form D) $30.5M.$0$10M$20M$30M$40M2022 · Private raises (Form D): $30.5M2022
Figures by year
YearPrivate raises (Form D)Total
2022$30.5M$30.5M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Sep 22, 2022Raised $13.3 million in a private offering of equity38 Form D: 13 investors so far Form D
  2. Sep 22, 2022Raised $17.2 million in a private offering of securities22 Form D: 10 investors so far Form D

SEC filer profile

How MediWound Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMediWound Ltd.1
  • CIK0001593984
  • Filer statusAccelerated filer not an emerging growth company; not a shell company39
  • Incorporated inIllinois39
  • Fiscal year endsDecember 311
  • Industry code (SIC)2833 Medicinal Chemicals & Botanical Products1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address42 Hayarkon Street, Yavne, L3 81227451
  • Phone9727797141001
  • Shares outstanding12,835,148 shares as of Dec 31, 202539
  • AuditorSomekh Chaikin, Tel Aviv, Israel PCAOB ID 1057; it also attests to the company’s internal control over financial reporting39
  • On EDGAR sinceDec 23, 20131
  • Filings393 in all: 6-K (205), SC 13G/A (32), SC 13G (20), 20-F (12), CORRESP (12), 3 (11), 424B3 (10), S-8 (10)1
    All 31 form types

    SCHEDULE 13G/A (10), UPLOAD (9), EFFECT (8), 424B5 (7), 4 (5), CT ORDER (5), F-3 (5), SC 13D/A (5), 6-K/A (3), DRS/A (3), F-1/A (3), SCHEDULE 13G (3), 144 (2), D (2), F-1 (2), SC 13D (2), 424B4 (1), 8-A12B (1), CERTNAS (1), DRS (1), POS AM (1), POS EX (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (20-F) Mar 5, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary shares, par value NIS 0.07 per shareMDWDNasdaq

From the cover page of the 20-F filed Mar 5, 2026 (Section 12(b) of the Exchange Act).39

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39